Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Gains from Investment Securities (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Gains from Investment Securities data on record, last reported at $258581.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to $258581.0; the TTM value through Sep 2025 reached $258581.0, changed N/A, while the annual FY2024 figure was $4.5 million, 157.2% up from the prior year.
  • Gains from Investment Securities reached $258581.0 in Q3 2025 per DNTH's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.5 million in Q4 2024 and bottomed at -$46000.0 in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $1.7 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: tumbled 108.68% in 2023, then soared 9881.96% in 2024.
  • A 4-year view of Gains from Investment Securities shows it stood at $529773.0 in 2022, then plummeted by 108.68% to -$46000.0 in 2023, then skyrocketed by 9881.96% to $4.5 million in 2024, then crashed by 94.25% to $258581.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $258581.0 in Q3 2025, $2.0 million in Q2 2025, and $1.6 million in Q1 2025.